Lead the team to do the right thing.
Release time:
2020-07-15
Group Company 2019 Outstanding Management Worker Zhang Baoping
Management Function of Jianfeng Pharmaceutical Factory is to lead the team to do the right thing, do the right thing, improve efficiency and create benefits. Under the correct leadership of the company in 2019, I will mainly assist the factory director in the following aspects:
1. to make a smooth transition for the merger of the two factories of Jinxi Factory and Qiubin Factory at the beginning of the year. The division of relevant post functions after the merger was completed, so that the merged pharmaceutical factory team carried out various tasks quickly and orderly, and better completed various management objectives for the whole year.
2. at the same time more in-depth promotion of the "three down three improve" work. Breakthroughs have been made in tackling key technological problems of some products, and the product quality and yield have been improved. Use automatic packaging lines instead of manual packaging to improve labor efficiency; Encourage relevant personnel to independently carry out energy-saving and consumption-reducing transformation; Adjust the production organization mode and adopt phased centralized production mode, which not only reduces the opportunity of cross-contamination between products but also reduces the operating cost of public systems.
3. take the initiative to communicate and strengthen the connection between production and marketing. Pay close attention to inventory changes, rationally formulate production plans, and try to coordinate the conflict between normal commercial production and new drug research and development and scale-up production, basically ensuring that product inventory meets sales needs.
4. to create a safe and environmentally friendly accident-free factory as a management goal. On the basis of strengthening investment in safety and environmental protection, clarifying responsibilities at all levels, carrying out safety risk identification and evaluation for all employees, and implementing various control measures, zero safety and environmental protection accidents were achieved in 2019.
As a manager, I am in awe of my work and dare not slack off. I always set an example. However, I know that compared with other advanced managers, there are still many shortcomings in personal work. I will continue to cultivate and improve myself and strive to make more contributions to the enterprise.
The task of 2020 will be more difficult and full of new challenges. I will continue to work hard, optimize ideas, further improve relevant systems, implement various control measures, effectively control risks, implement safe production, cost control, and standardized management, and strive to achieve better results. (According to Zhang Baoping's speech at the group company's summary commendation meeting)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page